# Methotrexate

## Methotrexate inj 50mg/2mL

| 藥物代碼 | IMTX2 |
| :--- | :--- |
| 適應症 | Trophoblastic tumors, leukemia, lymphoma, osteogenic & bronchogenic carcinoma, breast, head & neck cancer, mycosis fungoides. |
| 副作用 | Hepatotoxicity, GI, dermatological, liver & GUT toxicity. |
| 禁忌 | Pregnancy & lactation. Psoriatic patient in a poor state of nutrition, serious renal or liver disorders, bone marrow hyperplasia, leukopenia, thrombocytopenia or anemia. |
| 藥物保存方式 | N/A |
| 用法用量 | Choriocarcinoma: Oral or IM, 15-30 mg/day for a 5 day course. Acute leukemia: Induction, oral or IV, 3.3 mg/m2/day with prednisolone; maintenance, oral or IM, 30 mg/mL twice a week, or IV, 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal, 0.2-0.5 mg/kg or 12 mg/mL \(max. 15mg\) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma \(stage I & II\): Oral, 10-25 mg/day for 4-8 days. Psoriasis: Oral, IM or IV, 10-25 mg/week. Rheumatoid arthritis: Oral, 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral, 2.5-10 mg/day for weeks or months; IM, 50mg/week or 25mg twice a week. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | Contraindicated |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IM, IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | 【D5W】 可選  【N/S】 可選  【D5NS】 可選 |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. 本品為化療藥物，輸注時需注意注射部位，防止藥液外滲。 2. 監測CBC、肝腎功能。 |

## Methotrexate 2.5mg

| 藥物代碼 | OMTX |
| :--- | :--- |
| 適應症 | Oncology uses: Acute lymphoblastic leukemia \(ALL\) maintenance treatment, ALL meningeal leukemia \(preservative-free only; prophylaxis and treatment\); treatment of trophoblastic neoplasms \(gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole\), breast cancer, head and neck cancer \(epidermoid\), cutaneous T-Cell lymphoma \(advanced mycosis fungoides\), lung cancer \(squamous cell and small cell\), advanced non-Hodgkin lymphomas \(NHL\), osteosarcoma \(preservative-free only\). Nononcology uses: Treatment of psoriasis \(severe, recalcitrant, disabling\) that is unresponsive to other therapies; severe, active rheumatoid arthritis \(RA\) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents \(NSAIDs\); active polyarticular-course juvenile idiopathic arthritis \(pJIA\) that is unresponsive to or intolerant of first-line therapy including full dose nonsteroidal anti-inflammatory agents \(NSAIDs\). Off-Label: Abortion \(medical management\); Acute graft-versus-host disease \(prophylaxis\); Acute promyelocytic leukemia \(APL\) maintenance \(adults\); Bladder cancer; CNS lymphoma; Crohn disease \(maintenance of remission\); Dermatomyositis/polymyositis; Ectopic pregnancy; Multiple sclerosis; Nonleukemic meningeal cancer; Soft tissue sarcoma \(desmoid tumors, aggressive fibromatosis\), advanced; Systemic lupus erythematosus, moderate-to-severe; Takayasu arteritis, refractory or relapsing disease; Uveitis \(adults\) |
| 副作用 | Ulcerative stomatitis, leukopenia, nausea & abdominal distress. malaise, fatigue, chills & fever, dizziness & decreased resistance to infection. Erythematous rashes, pruritus, urticaria, photosensitivity, depigmentation, alopecia, ecchymosis, telangiectasia, acne & furunculosis. Hematologic disorders. GI disturbances. CNS effects. Metabolic changes, precipitating diabetes, osteoporosis, conjunctivitis, abnormal tissue cell changes, anaphylaxis. |
| 禁忌 | Known hypersensitivity to methotrexate or any component of the formulation; breast-feeding. Additional contraindications for patients with psoriasis, rheumatoid arthritis or polyarticular-course juvenile idiopathic arthritis: Pregnancy, alcoholism, alcoholic liver disease or other chronic liver disease, immunodeficiency syndromes \(overt or laboratory evidence\); preexisting blood dyscrasias \(eg, bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia\). |
| 藥物保存方式 | 室溫 |
| 用法用量 | Choriocarcinoma: Oral or IM, 15-30 mg/day for a 5 day course. Acute leukemia: Induction, oral or IV, 3.3 mg/m2/day with prednisolone; maintenance, oral or IM, 30 mg/mL twice a week, or IV, 2.5 mg/kg every 14 days. Meningeal leukemia: Intrathecal, 0.2-0.5 mg/kg or 12 mg/mL \(max. 15mg\) every 2-5 days until the cell count of cerebrospinal fluid returns to normal. Burkitt's lymphoma \(stage I & II\): Oral, 10-25 mg/day for 4-8 days. Psoriasis: Oral, IM or IV, 10-25 mg/week. Rheumatoid arthritis: Oral, 2.5 mg q12h for 3 doses every week. Mycosis fungoides: Oral, 2.5-10 mg/day for weeks or months; IM, 50mg/week. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 需 調 整 劑 量 |
| 懷孕用藥危分級 | 不可使用 |
| 孕期用藥建議 | Contraindicated - 1st trimester |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | Contraindicated 哺乳期使用禁忌 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

